Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SDZ 281-977 is a derivative of Lavendustin A which is the EGF receptor tyrosine kinase inhibitor.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 1,600 | 现货 | ||
5 mg | ¥ 2,710 | 现货 | ||
25 mg | ¥ 9,620 | 现货 | ||
50 mg | ¥ 12,500 | 现货 | ||
100 mg | ¥ 17,500 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,730 | 现货 |
产品描述 | SDZ 281-977 is a derivative of Lavendustin A which is the EGF receptor tyrosine kinase inhibitor. |
体外活性 | The anticancer profile of SDZ 281-977 is investigated in nude mice bearing the human tumor cell lines A431 (vulvar carcinoma cells), MIA PaCa-2 (pancreatic tumor cells), and MDA-MB-231 (breast carcinoma cells). For inhibition of growth of A431, MIA PaCa-2, and MDA-MB-231 cells the IC50 values are 0.21 μM, 0.29 μM, and 0.43 μM, respectively [1]. |
体内活性 | Nude mice bearing A431 human vulvar carcinomas receive intravenous injections of SDZ 281-977 (1-10 mg/kg) for 4 weeks. This treatment results in a dose-dependent inhibition of tumor growth. SDZ 281-977 (30 mg/kg, p.o.) treatment causes a 54% inhibition of A431 tumor growth after 3 weeks of treatment [1]. |
别名 | SDZ-LAP 977 |
分子量 | 316.35 |
分子式 | C18H20O5 |
CAS No. | 150779-71-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SDZ281-977 150779-71-8 Others SDZ281 977 SDZ-281-977 SDZ281977 SDZ-LAP 977 SDZ-LAP-977 SDZ-LAP977 Inhibitor inhibitor inhibit